Fresh analysis indicates that people who come off new weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass far faster than those who stop traditional diet and exercise regimens.
Published data in a prominent health publication shows that while obese people often shed a large proportion of their total mass while undergoing treatment, the weight returns at an average rate of nearly a kilo each month upon discontinuation.
"Users using these medications should be cognizant of the potential of fast rebound weight gain when the treatment is stopped," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery implies a return to pre-treatment mass within about one and a half years.
Analyzing Approaches
The study, which examined 37 of studies involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with conventional dieting.
Researchers note that people who shed pounds through dieting typically experience a less rapid weight regain—perhaps 0.1 kg a month—after stopping.
Understanding the Fast Regain
Nutrition scientists propose the mode of action of the injections explains the heightened weight return.
GLP-1 drugs copy a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 levels several times higher than normal could lead to the body to produce less of its endogenous GLP-1, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication means hunger is no longer kept in check, making overeating far more likely."
A Chronic Disease?
The NHS advise the jabs for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians say that, given the significant potential of weight regain, the therapy might need to be long-term.
This perspective is supported by drug manufacturers, who say that the findings "emphasize the long-term character of excess weight," comparing it to managing diseases like diabetes.
Patient Testimonies
People who have stopped the jabs report a powerful resurgence of hunger.
"It was like a trigger flipping and you become extremely hungry," described a patient.
The struggle is compounded if users have not established permanent lifestyle or habit modifications during therapy.
Significant Use
Survey data suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with demand being substantial.
- Adoption is greater among females than males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Ultimately, researchers stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a magic fix and long-term success hinges on ongoing behavioural management.
